Online inquiry

IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9318MR)

This product GTTS-WQ9318MR is a type of mRNA modified with N1-Methylpseudo-UTP, which ecodes the monoclonal antibody that targets HLA gene. The antibody can be applied in Melanoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001242524.2;
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3113; 3108; 3111; 3117; 3123
UniProt ID Q30058; P28067; P28068; P06340; P13765; O19764; E1ACV6
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-HLA, IMP-321(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9318MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14067MR IVTScrip™ mRNA-Anti-C5, REGN-3918(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-3918
GTTS-WQ222MR IVTScrip™ mRNA-Anti-IL13, 13C5.5(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 13C5.5
GTTS-WQ13459MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ4402MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ9249MR IVTScrip™ mRNA-Anti-MUC1, IMMU-107(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMMU-107
GTTS-WQ228MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
GTTS-WQ13387MR IVTScrip™ mRNA-Anti-PRLR, PR-1594804(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PR-1594804
GTTS-WQ1151MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 215
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW